[go: up one dir, main page]

DE60135675D1 - Behandlung von motorischen veränderungen mit 5-hydrxoytryptamin 1a rezeptor aktivität verstärkenden wirkstoffen - Google Patents

Behandlung von motorischen veränderungen mit 5-hydrxoytryptamin 1a rezeptor aktivität verstärkenden wirkstoffen

Info

Publication number
DE60135675D1
DE60135675D1 DE60135675T DE60135675T DE60135675D1 DE 60135675 D1 DE60135675 D1 DE 60135675D1 DE 60135675 T DE60135675 T DE 60135675T DE 60135675 T DE60135675 T DE 60135675T DE 60135675 D1 DE60135675 D1 DE 60135675D1
Authority
DE
Germany
Prior art keywords
hydrxoytryptamine
receptor activity
treatment
active substances
motor changes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60135675T
Other languages
English (en)
Inventor
Jonathan Brotchie
Michael Hill
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Motac Neuroscience Ltd
Original Assignee
Motac Neuroscience Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9902589&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60135675(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Motac Neuroscience Ltd filed Critical Motac Neuroscience Ltd
Application granted granted Critical
Publication of DE60135675D1 publication Critical patent/DE60135675D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Processing Of Meat And Fish (AREA)
  • Paper (AREA)
  • Threshing Machine Elements (AREA)
DE60135675T 2000-11-03 2001-10-29 Behandlung von motorischen veränderungen mit 5-hydrxoytryptamin 1a rezeptor aktivität verstärkenden wirkstoffen Expired - Lifetime DE60135675D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0027020.7A GB0027020D0 (en) 2000-11-03 2000-11-03 Treatment of movement disorders
PCT/GB2001/004774 WO2002036107A2 (en) 2000-11-03 2001-10-29 Treatment of motor fluctuations with 5-hydroxytryptamine 1a receptor activity enhancing coumpounds

Publications (1)

Publication Number Publication Date
DE60135675D1 true DE60135675D1 (de) 2008-10-16

Family

ID=9902589

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60135675T Expired - Lifetime DE60135675D1 (de) 2000-11-03 2001-10-29 Behandlung von motorischen veränderungen mit 5-hydrxoytryptamin 1a rezeptor aktivität verstärkenden wirkstoffen

Country Status (13)

Country Link
US (2) US20040067956A1 (de)
EP (1) EP1339398B1 (de)
JP (2) JP5189240B2 (de)
AT (1) ATE406880T1 (de)
AU (2) AU9580401A (de)
CA (1) CA2431641A1 (de)
CY (1) CY1108628T1 (de)
DE (1) DE60135675D1 (de)
DK (1) DK1339398T3 (de)
ES (1) ES2311549T3 (de)
GB (1) GB0027020D0 (de)
PT (1) PT1339398E (de)
WO (1) WO2002036107A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9924941D0 (en) * 1999-10-22 1999-12-22 Univ Manchester Treatment of dyskinesia
GB0027020D0 (en) 2000-11-03 2000-12-20 Univ Manchester Treatment of movement disorders
US9066903B2 (en) * 2006-02-28 2015-06-30 The United States Of America As Represented By The Department Of Veterans Affairs Pharmacological treatment of Parkinson's disease
MX372641B (es) * 2012-10-22 2020-06-15 Merz Pharmaceuticals Llc Formulaciones de levodopa para el alivio rapido de la enfermedad de parkinson.
WO2020087031A1 (en) 2018-10-26 2020-04-30 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
CN116113402A (zh) * 2020-08-31 2023-05-12 住友制药株式会社 帕金森病的运动并发症治疗药

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2126554A1 (en) * 1992-01-07 1993-07-22 Martin Galvan Treatment of involuntary movements with 5ht1a receptor agonists
EP0697894A4 (de) * 1993-03-31 1996-05-01 Univ Pennsylvania Dopamin d-3 und serotonin (5-ht 1a) rezeptor-liganden und bildgebunde mittel
GB9408084D0 (en) * 1994-04-23 1994-06-15 Boots Co Plc Medical treatment
GB9815618D0 (en) * 1998-07-18 1998-09-16 Univ Manchester Treatment of dyskinesia
HN1999000146A (es) * 1998-09-21 2000-11-11 Pfizer Prod Inc Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas.
US6136559A (en) * 1998-10-07 2000-10-24 Ortho Pharmaceutical Corporation DNA encoding as human histamine receptor of the H3 subtype
GB9924941D0 (en) * 1999-10-22 1999-12-22 Univ Manchester Treatment of dyskinesia
GB0027020D0 (en) 2000-11-03 2000-12-20 Univ Manchester Treatment of movement disorders
PT1539135E (pt) * 2002-09-17 2007-07-12 Motac Neuroscience Ltd Tratamento da discinesia.
US7786126B2 (en) * 2006-06-16 2010-08-31 Solvay Pharmaceuticals B.V. Combination preparations comprising SLV308 and a dopamine agonist
EA015073B1 (ru) 2006-06-16 2011-04-29 Солвей Фармасьютикалс Б.В. Комбинированные препараты, содержащие slv308 и l-dopa
CA2694572A1 (en) 2007-11-30 2009-06-04 Asubio Pharma Co., Ltd. Drug for alleviating motor complications or psychiatric symptoms of parkinson's disease

Also Published As

Publication number Publication date
ATE406880T1 (de) 2008-09-15
CA2431641A1 (en) 2002-05-10
AU9580401A (en) 2002-05-15
EP1339398B1 (de) 2008-09-03
AU2001295804B2 (en) 2007-01-04
PT1339398E (pt) 2008-11-03
US9668995B2 (en) 2017-06-06
DK1339398T3 (da) 2009-01-26
JP2010241827A (ja) 2010-10-28
GB0027020D0 (en) 2000-12-20
WO2002036107A3 (en) 2003-01-16
EP1339398A2 (de) 2003-09-03
US20040067956A1 (en) 2004-04-08
ES2311549T3 (es) 2009-02-16
WO2002036107A2 (en) 2002-05-10
CY1108628T1 (el) 2014-04-09
JP5189240B2 (ja) 2013-04-24
JP2004512360A (ja) 2004-04-22
US20110178178A1 (en) 2011-07-21

Similar Documents

Publication Publication Date Title
ATE227597T1 (de) Implantat
DE60022226D1 (de) Benzimidazolverbindungen die nociceptinrezeptoraffinität haben
FI954944A0 (fi) Indolijohdannaisia 5-HT1-kaltaisina agonisteina käytettäväksi migreenin hoitoon
ATE288747T1 (de) Methoden und zusammensetzungen zur modulierung der aktivität von alpha-adrenergen rezeptoren
DE60035639D1 (de) Hydroxydiphenyletherverbindungen
DK1225881T3 (da) Anvendelsen af dapoxetin, en hurtigt-virkende selektiv serotonin genoptagelseshæmmer, til behandling af seksuel dysfunktion
TR200103119T2 (tr) Göz kurumasının tedavisi için madde.
EA199900912A1 (ru) Фармацевтические средства
CY1108628T1 (el) Θεραπεια των κινητικων διακυμανσεων με ενωσεις ενισχυσης της δραστηριοτητας του υποδοχεα 5-υδροξυτρυπταμινη 1α
NO20032762L (no) Aktivitetsstyringsanordning
MXPA02006167A (es) Promocion de la angiogenesis con survivina.
ITRM990426A0 (it) Impiego di inibitori della sostanza p per il trattamento degli adenocarcinomi.
ATE333277T1 (de) Behandlung von dyskinesie
ATE460938T1 (de) Morpholin-derivate zur verwendung als dopaminagonisten in der behandlung von u.a. sexueller dysfunktion
AR008860A1 (es) Empleo de 1-hidroxi-2-piridonas para el tratamiento de la dermatitis seborreica
NO20032406D0 (no) Anvendelse av 1-fenyl-3-dimetylaminopropanforbindelser for behandling av urininkontinens
ATE346040T1 (de) Aryl-sulfonamide als serotonin-antagonisten für de behandlung von fettleibigkeit
DE602004021704D1 (de) Wirksubstanzkombination mit einer verbindung mit npy rezeptor-affinität und einer verbindung mit 5-ht6 rezeptor-affinität
DK1177191T3 (da) Substituerede benzimidazoler, fremstilling og anvendelse deraf som midler til bekæmpelse af parasitiske protozoer
ATE345135T1 (de) Tropan-derivate mit dopamin-wiederaufnahme-hemmer-wirkung für die behandlung von ischämischen erkrankungen
ATE323493T1 (de) Gesteuerte freisetzung von antidepressiva
DE60222552D1 (de) Carbamate von 2-heterozyklischen 1,2-ethandiolen
DK1459748T3 (da) (S,S)-reboxetin til behandling af perifer neuropati
DK1332229T3 (da) Fremgangsmåde til screening af midler til at behandle overvægt
TR199902914T2 (xx) �zole sistolik hipertansiyonu tedavi y�ntemi.

Legal Events

Date Code Title Description
8363 Opposition against the patent